Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Aim COVID-19 clinical presentation is heterogeneous, ranging from asymptomatic to severe
cases. While there are a number of early publications relating to risk factors for COVID-19 …
cases. While there are a number of early publications relating to risk factors for COVID-19 …
COVID-19 in immunocompromised hosts: what we know so far
M Fung, JM Babik - Clinical Infectious Diseases, 2021 - academic.oup.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
EM Bange, NA Han, P Wileyto, JY Kim, S Gouma… - Nature medicine, 2021 - nature.com
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Background Individuals with cancer, particularly those who are receiving systemic
anticancer treatments, have been postulated to be at increased risk of mortality from COVID …
anticancer treatments, have been postulated to be at increased risk of mortality from COVID …
Determinants of COVID-19 disease severity in patients with cancer
EV Robilotti, NE Babady, PA Mead, T Rolling… - Nature medicine, 2020 - nature.com
Abstract As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer …
syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer …
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …
[HTML][HTML] Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer …
Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
[HTML][HTML] Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies
Background Patients with coronavirus disease 2019 (COVID-19) who have underlying
malignancy have a higher mortality rate compared with those without cancer, although the …
malignancy have a higher mortality rate compared with those without cancer, although the …